Alogliptin (Benzoate)

Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of [1][2][3].

Product Specifications

CAS Number

[850649-62-6]

Product Name Alternative

SYR 322

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Dipeptidyl Peptidase; Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/alogliptin-benzoate.html

Purity

99.98

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 14.29 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C=C(N1C[C@H](N)CCC1)N(C2=O)CC3=C(C#N)C=CC=C3)N2C.O=C(O)C4=CC=CC=C4

Molecular Formula

C25H27N5O4

Molecular Weight

461.51

Precautions

H302, H312, H332

References & Citations

[1]Feng J, et, al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50 (10) :2297-300.|[2]Ta NN, et, al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213 (2) :429-35.|[3]Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187.|[4]Asakawa T, et, al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85 (3-4) :122-6.|[5]Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602 (2-3) :448-54.